Onena Medicines

Onena Medicines is a biopharmaceutical company with a pipeline of first-in-class antibody medicines to treat recurrent and metastatic cancers and selected rare diseases. Onenas drugs neutralize a new class of secreted ancient growth factors, conserved across species, called Dual SMAD Inhibiting Proteins (DSIPs), that program cancer cells to grow and resist chemotherapy. Blocking DSIPs, as demonstrated in-vivo by Onena, simultaneously reactivates physiological TGF- and BMP signaling and elicits cellular reprogramming, resulting in cancer cells accepting environmental cell death signals from BMPs and Activins. Onena has developed a proprietary AI-centric antibody drug discovery platform that rapidly generates anti-DSIP neutralizing antibodies, even...

Oncology,antibody engineering,rare diseases,biotechnology,biologics,drug discovery,drug development,assay,cancer,patient,clinical,clinical trial,switzerland,spain,and basel

Onena medicines operates in the Biotechnology industry.

Onena medicines's revenue is 1m - 10m

Onena medicines has 11 - 50 employees.